Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000596

Drug Information
NameDyphylline
SynonymsCOR-theophylline; 7-(2,3-Dihydroxypropyl)-1,3-dimethylxanthine; Silbephylline; KBioGR_001139; Glyfyllin; Prestwick0_000033; dyphylline; Circair; 7-(beta,gamma-Dihydroxypropyl)theophylline; D3600; Diprophylline; Isophyllen; Propyphyllin; Glyphyllinum; NSC40844; Glyphyllin; KSCFJBIXMNOVSH-UHFFFAOYSA-; BSPBio_000125; AC-11186; DivK1c_000022; 37910_FLUKA; NCGC00089736-03; Dyphylline (USP); NCGC00178894-02; Teofen; Lufyllin; EINECS 207-526-1; 52756-53-3; Spectrum_000809; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-, (+-)-; Prestwick2_000033; Astrophyllin; Spectrum2_000090; Oprea1_363458; InChI=1/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3; Neutraphylline; 7-(2,3-dihydroxypropyl)-1,3-dimethylpurine-2,6-dione; (+-)-dyphylline; STK796769; Purifilin; BB_NC-1985; NSC 14305; KBioSS_001289; CHEMBL1752; Diprofilline; Solufyllin; Theal ampules; 479-18-5; LS-149505; Aristophyllin; Dihydroxypropyl theophylline; Diprophylline (JAN/INN); DB00651; SMR000059068; Coronarin; Neophylline; NSC14305; Diprophyllinum; SMP1_000108; Neophyllin M; (1,2-Dihydroxy-3-propyl)thiophyllin; Dihydroxypropyl theopylin; KBio2_006425; Tefilan; 5-26-14-00070 (Beilstein Handbook Reference); KBio2_003857; MLS000069403; Diprofillin; MolPort-001-783-701; Thefylan; Lufyllin (TN); Hiphyllin; Tesfen; I14-5830; Prestwick1_000033; Diprofillina; Theophylline, 7-(2,3-dihydroxypropyl)-; BSPBio_001962; HSDB 3322; Astmamasit; D00691; 7-(2,3-Dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione; AB00051977; Diprophyllinum [INN-Latin]; Solufilin; Droxine; Dyflex; Dyphylline [USAN]; Prestwick_465; Neufil; 7-DIHYDROXYPROPYLTHEOPHYLLINE; Diprofilina; Theal; Diphyllin (VAN); Spectrum5_000953; Coronal; AC1Q3Z7Q; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl; Diprophyllin; Neutrafil; WLN: T56 BN DN FNVNVJ B1YQ1Q F1 H1; HMS2091B13; SPECTRUM1500269; CID3182; SPBio_000020; AR-1I7082; AC1L1FCW; AC1Q6LEB; Hyphylline; Neothylline; Dipropylline; Dilor-400; 7-[2,3-Dihydroxypropyl]-theophylline; KBio2_001289; Spectrum3_000411; HMS1920K08; 7-(2,3-Dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione; Neo-Vasophylline; Neutroxantina; Corphyllin; Synthophylline; Hidroxiteofillina; NCGC00089736-02; HMS500B04; 7-(.beta.,.gamma.-Dihydroxypropyl)theophylline; UNII-263T0E9RR9; KBio3_001182; IDI1_000022; C10H14N4O4; Soluphyllin; SPBio_002046; BRN 0284563; AFI-Phyllin; Neutraphyllin; Iphyllin; Silbephyllin; S1504_Selleck; (+-)-diprophylline; Neostenovasan; Dihydroxypropyltheophylline; MLS001076466; NCGC00178894-01; Circain; Asthmolysin; D0633_SIGMA; 1H-Purine-2,6-dione, 7-(2,3-dihydroxypropyl)-3,7-dihydro-1,3-dimethyl-; KBio1_000022; Dihydroxypropyl theopylin (german); 7-(2,3-dihydroxypropyl)-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione; Liactemin; 7-(2,3-Dioxypropyl)theophylline; Spectrum4_000530; Neothylline, Lufyllin, diprophylline,Dyphylline; Neophyl; C07819; Neophyllin; Prestwick3_000033; Protheophylline; Glyphylline; BPBio1_000139; NINDS_000022; 7-(2,3-Dihydroxypropyl)theophylline; CHEBI:4728; Diprofilina [INN-Spanish]; (+-)-7-(2,3-Dihydroxypropyl)theophylline; 1,3-Dimethyl-7-(2,3-dihydroxypropyl)xanthine; Neutrafillina; BRD-A00827783-001-05-5; HMS1568G07; Diprofillina [DCIT]; Neotilina; Dilor G; SR-01000002972-2
IndicationAcute bronchial asthma
[ICD9: 493   ICD10: J45]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/
h5-6,15-16H,3-4H2,1-2H3
InChIKeyKSCFJBIXMNOVSH-UHFFFAOYSA-N
Canonical SMILESCN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O    
Therapeutic ClassBronchodilator Agents
CAS NumberCAS 479-18-5
FormulaC10H14N4O4
PubChem Compound IDCID 3182.
PubChem Substance IDSID 10021.
SuperDrug ATC IDR03DA01
SuperDrug CAS ID000479185;
TargetCAMP-specific 3',5'-cyclic phosphodiesterase 4AInhibitor[2]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 007794 To Reference
Ref 2Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543